Liminatus Pharma Charts Dual-Front Attack on Cancer with IBA101
Liminatus Pharma, Inc (NASDAQ:LIMN) LA PALMA, CA, UNITED STATES, June 24, 2025 /EINPresswire.com/ -- Next-generation CD47 inhibitor advances toward human trials in U.S. and Korea, with the prospect of safer, more potent immunotherapy Since …